Insulin aspart–pramlintide

Insulin aspart–pramlintide is a therapeutic combination consisting of a rapid-acting insulin analog and a synthetic analog of the human hormone amylin. In healthy individuals, insulin and amylin are co-secreted by pancreatic beta cells to regulate postprandial glucose levels; however, both hormones are deficient in patients with type 1 diabetes and advanced type 2 diabetes (NIH, 2024). This combination therapy aims to restore the physiological synergy between these two hormones to provide superior glycemic control compared to insulin monotherapy. Insulin aspart facilitates peripheral glucose uptake and suppresses hepatic glucose output, while pramlintide slows gastric emptying, inhibits inappropriate post-meal glucagon secretion, and promotes satiety (StatPearls, 2023). Advanced co-formulations, such as BioChaperone Pramlintide Insulin, utilize specialized excipients to overcome the chemical incompatibility of the two peptides, which typically require different pH environments for stability. By allowing for a single injection, this dual-hormone approach mimics endogenous pancreatic function, potentially reducing postprandial glucose excursions and the risk of weight gain associated with intensive insulin therapy (Adocia, 2018).

Other names

Pramlintide/Insulin aspart co-formulationBioChaperone Pramlintide InsulinBC Pram InsADOCIA BioChaperone Pramlintide Insulin

Insulin aspart is a rapid-acting insulin analog that binds to and activates the insulin receptor (INSR), a receptor tyrosine kinase, to stimulate glucose uptake in skeletal muscle and adipose tissue while inhibiting hepatic glucose output (PubChem, 2024). Pramlintide is a synthetic analog of amylin that acts as an agonist at amylin receptors (AMY), which are heterodimeric complexes of the calcitonin receptor (CTR) and receptor activity-modifying proteins (RAMP1, RAMP2, or RAMP3). Activation of these receptors in the central nervous system leads to a reduction in postprandial glucagon secretion, a delay in gastric emptying, and an increase in satiety, collectively lowering postprandial glucose excursions (PubMed, 2021).